Ozempic Gastroparesis Settlement: Statute of Limitations for Ozempic in Illinois

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Assessment

The legacy domain of general health and science information has long provided foundational knowledge on medication safety, disease prevention, and public health guidelines. Within this framework, discussions of pharmaceutical interventions have historically emphasized benefits and broad risk profiles, often focusing on metabolic conditions such as diabetes and weight management. As public awareness of medication side effects has grown, the focus has expanded to include specific adverse events linked to widely prescribed drugs. This evolution in health communication now requires a more targeted examination of how certain medications may impact patient populations in distinct contexts, including occupational settings where exposure patterns differ from general use. Transitioning from this broad heritage, the concern shifts to occupational exposure scenarios involving glucagon-like peptide-1 receptor agonists, such as Ozempic. In mass production environments, workers may encounter these substances through manufacturing, handling, or accidental contact, raising questions about long-term health implications. Specifically, the potential association between such exposure and gastrointestinal motility disorders, including gastroparesis, has prompted legal and regulatory scrutiny. In Illinois, the statute of limitations for filing claims related to Ozempic-associated gastroparesis becomes a critical consideration for affected individuals, particularly those with occupational exposure histories. This pivot from general health information to a focused occupational risk assessment underscores the need for precise timelines and legal awareness in addressing potential liabilities.

Ozempic and Gastroparesis: Medical Evidence and Risk Context

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which contributes to glycemic control but also underlies a spectrum of gastrointestinal adverse effects. Clinical trial data demonstrate that gastrointestinal adverse reactions occur significantly more frequently among patients receiving Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea episodes occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps with the common gastrointestinal adverse effects of Ozempic, including nausea (reported in 15.8% of patients on 0.5 mg and 20.3% on 1 mg, versus 6.1% on placebo), vomiting (5.0% and 9.2% versus 2.3%), diarrhea (8.5% and 8.8% versus 1.9%), and abdominal pain (7.3% and 5.7% versus 4.6%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Constipation was also reported (5.0% on 0.5 mg, 3.1% on 1 mg, versus 1.5% on placebo) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanistic pathway linking Ozempic to gastroparesis involves its GLP-1 receptor agonist activity, which delays gastric emptying through inhibition of antral contractions and stimulation of pyloric tone. While this effect is intended for glycemic control, prolonged or exaggerated delay can lead to symptomatic gastroparesis, particularly in susceptible individuals.

Adequacy of Warnings and Legal Implications in Illinois

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema, but does not explicitly list gastroparesis as a warning or precaution (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label notes that gastrointestinal adverse reactions are common and often occur during dose escalation, but it does not specifically address the risk of developing gastroparesis as a distinct condition. This gap in labeling may affect patients' ability to recognize and report symptoms early, potentially delaying diagnosis and treatment. For affected patients in Illinois, settlement-related considerations hinge on whether the manufacturer provided adequate warnings about the risk of gastroparesis. If warnings were insufficient, patients who developed gastroparesis after using Ozempic may have grounds for legal claims. The timeline between exposure to Ozempic and documented harm is another important factor. Gastrointestinal adverse reactions, including those consistent with gastroparesis, typically emerge during dose escalation, as noted in clinical trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the onset of gastroparesis may be delayed or progressive, with symptoms persisting or worsening over time. In Illinois, the statute of limitations for personal injury claims generally requires filing within two years from the date the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means patients must be aware of the link between their symptoms and the medication to trigger the limitations period. Given that gastrointestinal symptoms are common and may be attributed to other causes, the discovery date may be later than the initial symptom onset, which could affect the timeliness of claims. Settlement considerations for affected patients include the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the individual's medical history. Patients with pre-existing gastrointestinal conditions or those who experienced severe or persistent symptoms may have stronger claims. The availability of clinical trial data showing a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo supports a causal association, but the absence of a specific gastroparesis warning in the label may be a point of contention. Legal counsel should evaluate the specific circumstances of each case, including the timing of symptoms relative to Ozempic use and any documentation of gastroparesis diagnosis. In summary, the evidence indicates that Ozempic is associated with a higher rate of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, compared to placebo. The mechanistic link through delayed gastric emptying is plausible, but the prescribing information does not explicitly warn about gastroparesis. For Illinois patients, the statute of limitations and settlement considerations depend on the adequacy of warnings, the timeline of harm, and individual medical factors. Patients who believe they have developed gastroparesis due to Ozempic should seek medical evaluation and legal advice promptly.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Illinois?

In Illinois, the statute of limitations for personal injury claims generally requires filing within two years from the date the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means the clock starts when the patient becomes aware of the link between their symptoms and the medication. Because gastrointestinal symptoms are common and may be misattributed, the discovery date may be later than initial symptom onset, potentially extending the filing window. It is crucial to consult with an attorney promptly to evaluate your specific timeline.

Does Ozempic's prescribing information warn about gastroparesis?

No, the prescribing information for Ozempic does not explicitly list gastroparesis as a warning or precaution. It includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema, and notes that gastrointestinal adverse reactions are common, especially during dose escalation. However, it does not specifically address the risk of developing gastroparesis as a distinct condition. This gap in labeling may affect patients' ability to recognize and report symptoms early, and could be a factor in legal claims regarding inadequate warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.